Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin?6 (IL-6) i...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2020-05-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/1731 |